|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| A61K 31/506 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61P 35/02 | (2018.01) |
| (11) | Number of the document | 3302485 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16804177.0 |
| Date of filing the European patent application | 2016-05-27 | |
| (97) | Date of publication of the European application | 2018-04-11 |
| (45) | Date of publication and mention of the grant of the patent | 2023-07-12 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/034861 |
| Date | 2016-05-27 |
| (87) | Number | WO 2016/196385 |
| Date | 2016-12-08 |
| (30) | Number | Date | Country code |
| 201562168530 P | 2015-05-29 | US | |
| 201562263582 P | 2015-12-04 | US |
| (72) |
PANDEY, Anjali , US
COFFEY, Gregory , US
LEEDS, Janet , US
|
| (73) |
Alexion Pharmaceuticals, Inc. ,
121 Seaport Boulevard, Boston, MA 02210,
US
|
| (54) | CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |
| CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |